Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study
NCT ID: NCT00006177
Last Updated: 2023-03-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
1303 participants
Study Classification
OBSERVATIONAL
Study Start Date
2000-08-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This research protocol seeks to learn more about bipolar disorder in children and adolescents ages 6-17. Researchers will describe the moods and behaviors of children with bipolar disorder and use specialized testing and brain imaging to learn about specific brain changes associated with the disorder. This protocol studies children who have been diagnosed with bipolar disorder, and those who have a sibling or parent with bipolar disorder and are thus considered "at risk" for developing the disorder.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
NCT00025935
Mood Disorder
RECRUITING
Brain Imaging and Computer Games in Children With Either Bipolar Disorder, ADHD, Anxiety or Healthy Controls
NCT01570426
Bipolar Disorder
Attention Deficit Disorder With Hyperactivity
Attention Deficit Disorder Without Hyperactivity
+2 more
UNKNOWN
Pediatric Bipolar Disorder Study at UCLA
NCT00961935
Bipolar Disorder
COMPLETED
The Treatment of Children and Adolescents With Treatment-Resistant Depression
NCT00029640
Bipolar Disorder
COMPLETED
Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder
NCT00338806
Bipolar Disorder
Depression
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective:
For this protocol we define Bipolar Spectrum disorders (BSD) as the propensity to have a manic episode by having Bipolar Disorder or Substance/Medication-Induced Bipolar and Related Disorder. BSD in children and adolescents is receiving increased research attention, but important questions remain about its developmental trajectory, phenomenology and behavioral correlates, and little is known about its underlying neural mechanisms. In its study of youth with BSD, this study has three objectives:
1. to use longitudinal techniques to characterize the clinical and physiological manifestations of pediatric BSD, and to use cross-sectional techniques (e.g., comparing children and adults with BSD on these measures) to provide preliminary data to guide such longitudinal studies
2. to identify and follow longitudinally behavioral, neuropsychological, neurophysiological, and neuroanatomical correlates of pediatric BSD, and compare to children with chronic irritability and hyperarousal symptoms (severe mood dysregulation, SMD, as outlined in protocol 02-M-0021), youth with attention deficit hyperactivity disorder (ADHD), and typically developing youth.
3. to examine genetic and familial correlates of pediatric BSD
Study population:
There are 11 separate populations being studied in this protocol:
1. Children and adolescents between the ages of 6-17 years old who meet criteria for BSD.
2. Adults between the ages of 18-58 years old who meet criteria for BD, including those age 18-25 with BSD.
3. Control populations of: a) Healthy volunteer children and adolescents between the ages of 3-17 years old, b) Parents of healthy volunteer children or healthy adults in research, c) Children 8-17 years old with attention deficit hyperactivity disorder (ADHD), who do not have a mood disorder.
4. First and second-degree biological relatives of those in (B.1) or (B.2), above, and are between 3-58 years old.
5. A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for (1), (2), (3a), (3b), or (4).
Design:
For children and adolescents with BSD (i.e. Bipolar Disorder or those with Substance/Medication-Induced Bipolar and Related Disorder), this study is an outpatient characterization and longitudinal follow-along design. Once determined to be eligible, individuals come for an initial assessment, and then at varying intervals they return for clinical interviews, behavioral tasks, and structural and functional MRI.
For children and adolescents who are relatives of individuals with BSD, this is an outpatient follow-along design during which individuals come for an outpatient assessment and at 2-year intervals for clinical interviews, behavioral tasks, and structural and functional MRI.
For healthy volunteer children, children with only ADHD, adults with BD, and parents of healthy volunteer children, this study is an outpatient cross-sectional study that includes clinical interviews, behavioral tasks, and structural and functional MRI.
For all others, individuals come to NIH for clinical interviews, behavioral tasks, and MRI.
For most individuals in the Amish community, the investigation occurs in the field, where they receive clinical interviews and behavioral tasks. Some may choose to come to the NIH to participate in behavioral testing and MRI.
For all individuals, genetic material from saliva or blood is obtained under protocol 01-M-0254.
Outcome measures:
This study will examine between group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with BSD, their relatives, and healthy volunteers. Findings in children with BSD will also be compared to those with severe mood dysregulation, sometimes called a broad phenotype of pediatric BD, recruited under protocol 02-M-0021 (Nottelman, 2001).
Longitudinal clinical, behavioral, and neuroanatomical data will also be obtained.
For this protocol we define Bipolar Spectrum disorders (BSD) as the propensity to have a manic episode by having Bipolar Disorder or Substance/Medication-Induced Bipolar and Related Disorder. BSD in children and adolescents is receiving increased research attention, but important questions remain about its developmental trajectory, phenomenology and behavioral correlates, and little is known about its underlying neural mechanisms. In its study of youth with BSD, this study has three objectives:
1. to use longitudinal techniques to characterize the clinical and physiological manifestations of pediatric BSD, and to use cross-sectional techniques (e.g., comparing children and adults with BSD on these measures) to provide preliminary data to guide such longitudinal studies
2. to identify and follow longitudinally behavioral, neuropsychological, neurophysiological, and neuroanatomical correlates of pediatric BSD, and compare to children with chronic irritability and hyperarousal symptoms (severe mood dysregulation, SMD, as outlined in protocol 02-M-0021), youth with attention deficit hyperactivity disorder (ADHD), and typically developing youth.
3. to examine genetic and familial correlates of pediatric BSD
Study population:
There are 11 separate populations being studied in this protocol:
1. Children and adolescents between the ages of 6-17 years old who meet criteria for BSD.
2. Adults between the ages of 18-58 years old who meet criteria for BD, including those age 18-25 with BSD.
3. Control populations of: a) Healthy volunteer children and adolescents between the ages of 3-17 years old, b) Parents of healthy volunteer children or healthy adults in research, c) Children 8-17 years old with attention deficit hyperactivity disorder (ADHD), who do not have a mood disorder.
4. First and second-degree biological relatives of those in (B.1) or (B.2), above, and are between 3-58 years old.
5. A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for (1), (2), (3a), (3b), or (4).
Design:
For children and adolescents with BSD (i.e. Bipolar Disorder or those with Substance/Medication-Induced Bipolar and Related Disorder), this study is an outpatient characterization and longitudinal follow-along design. Once determined to be eligible, individuals come for an initial assessment, and then at varying intervals they return for clinical interviews, behavioral tasks, and structural and functional MRI.
For children and adolescents who are relatives of individuals with BSD, this is an outpatient follow-along design during which individuals come for an outpatient assessment and at 2-year intervals for clinical interviews, behavioral tasks, and structural and functional MRI.
For healthy volunteer children, children with only ADHD, adults with BD, and parents of healthy volunteer children, this study is an outpatient cross-sectional study that includes clinical interviews, behavioral tasks, and structural and functional MRI.
For all others, individuals come to NIH for clinical interviews, behavioral tasks, and MRI.
For most individuals in the Amish community, the investigation occurs in the field, where they receive clinical interviews and behavioral tasks. Some may choose to come to the NIH to participate in behavioral testing and MRI.
For all individuals, genetic material from saliva or blood is obtained under protocol 01-M-0254.
Outcome measures:
This study will examine between group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with BSD, their relatives, and healthy volunteers. Findings in children with BSD will also be compared to those with severe mood dysregulation, sometimes called a broad phenotype of pediatric BD, recruited under protocol 02-M-0021 (Nottelman, 2001).
Longitudinal clinical, behavioral, and neuroanatomical data will also be obtained.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bipolar Disorder
Mood Disorders
Attention Deficit Hyerpactivity Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adult bipolar patients
Adult bipolar patients
No interventions assigned to this group
Adult Extended Relatives of BD probands
Adult Extended Relatives of BD probands
No interventions assigned to this group
Bipolar Children and Youth
Bipolar Children and Youth
No interventions assigned to this group
Child/Adolescent Extended Relatives of BD probands
Child/Adolescent Extended Relatives of BD probands
No interventions assigned to this group
Children with ADHD only (controls)
Children with ADHD only (controls)
No interventions assigned to this group
First degree relatives of BD patients
First degree relatives of BD patients
No interventions assigned to this group
Healthy volunteer adults (parents or not)
Healthy volunteer adults (parents or not)
No interventions assigned to this group
Healthy volunteer children and youth
Healthy volunteer children and youth
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 6-17
* Meet DSM criteria for BD
* Have a primary caregiver who can accompany him or her on trips to NIMH and provide reliable history and information.
* Have a psychiatrist who provides clinical care for their BSD.
* Be able to complete self-rating forms and to cooperate with other study procedures.
* DSM Bipolar Disorder
* Age 18-58
* Be able to complete self-rating forms and to cooperate with other study procedures.
* Medically safe to perform MRI
* Age- and sex- matched to the bipolar patients.
* Have an identified primary care physician.
* Speaks English
* For healthy adults (not parents): Healthy adults age 25-58
* For parents of healthy volunteers: Parents of control subjects as outlined in B above
* Age 25-58
* Speaks English
* Age 8-17
* Currently meets DSM-IV criteria for ADHD
* t score \>65 on the Connors Parent scales
* Subjects with other psychiatric disorders including anxiety disorders, dysthymic disorder, past major depression, oppositional defiant disorder, tic disorders, and the learning, communication, and elimination disorders may be accepted
* First degree relatives (parent or sibling) or second-degree relative (grandparent, grandchild, uncle, aunt, nephew, niece, half-sibling) of patients with BD
* Age 3-58
* Age 8-17
* Meet DSM-IV criteria for BD
* Have a primary caregiver who can provide a reliable history
* Be able to complete self-rating forms and to cooperate with other study procedures.
* DSM-IV Bipolar Disorder
* Age 18-58
* Be able to complete self-rating forms and to cooperate with other study procedures.
* Age 8-17
* Parent or sibling (first-degree relative) diagnosed with BD
* Age 8-17
* No serious physical or neurological symptoms or disorder by history
* Age 18-58
* No serious physical or neurological symptoms or disorder by history
* For Parents of child with BD or spouses of patient with BD: Spouse or offspring with BD
Treatment failure as defined by current CGAS score \<60
The child s psychiatrist/treating physician agrees that a change in medication regimen is appropriate
* Meet DSM criteria for BD
* Have a primary caregiver who can accompany him or her on trips to NIMH and provide reliable history and information.
* Have a psychiatrist who provides clinical care for their BSD.
* Be able to complete self-rating forms and to cooperate with other study procedures.
* DSM Bipolar Disorder
* Age 18-58
* Be able to complete self-rating forms and to cooperate with other study procedures.
* Medically safe to perform MRI
* Age- and sex- matched to the bipolar patients.
* Have an identified primary care physician.
* Speaks English
* For healthy adults (not parents): Healthy adults age 25-58
* For parents of healthy volunteers: Parents of control subjects as outlined in B above
* Age 25-58
* Speaks English
* Age 8-17
* Currently meets DSM-IV criteria for ADHD
* t score \>65 on the Connors Parent scales
* Subjects with other psychiatric disorders including anxiety disorders, dysthymic disorder, past major depression, oppositional defiant disorder, tic disorders, and the learning, communication, and elimination disorders may be accepted
* First degree relatives (parent or sibling) or second-degree relative (grandparent, grandchild, uncle, aunt, nephew, niece, half-sibling) of patients with BD
* Age 3-58
* Age 8-17
* Meet DSM-IV criteria for BD
* Have a primary caregiver who can provide a reliable history
* Be able to complete self-rating forms and to cooperate with other study procedures.
* DSM-IV Bipolar Disorder
* Age 18-58
* Be able to complete self-rating forms and to cooperate with other study procedures.
* Age 8-17
* Parent or sibling (first-degree relative) diagnosed with BD
* Age 8-17
* No serious physical or neurological symptoms or disorder by history
* Age 18-58
* No serious physical or neurological symptoms or disorder by history
* For Parents of child with BD or spouses of patient with BD: Spouse or offspring with BD
Treatment failure as defined by current CGAS score \<60
The child s psychiatrist/treating physician agrees that a change in medication regimen is appropriate
Exclusion Criteria
Pediatric patients with bipolar disorder or SMIBRD:
* I.Q. \< 70
* Autistic disorder or more than mild autism spectrum disorder;
* Psychosis that interferes with the child s capacity to understand and comply with study procedures
* Unstable medical illness (e.g. severe asthma)
* Medical illness that could cause the symptoms of BSD (e.g. multiple sclerosis, thyroid disease)
* Pregnancy
* Substance abuse within two months of the initial evaluation, since alcohol and abused substances interfere with interpretation of fMRI and cognitive task data.
* NIMH IRP Employee family member
Adults with BD participating as individuals or as parents of at- risk children:
* Diagnosis of schizophrenia or other current psychosis.
* Claustrophobia or anxiety that prevents participation in MRI
* Any serious medical illness, such as heart, liver, or kidney disease.
* A history of drug or alcohol abuse in the past 90 days.
* Current or past seizure disorder
* Currently unstable hyperthyroidism or hypothyroidism
* Currently receiving medical treatment that would affect mood, such as steroids
* Pregnant or breast-feeding.
* Active suicidal or homicidal thoughts or plans
* NIMH IRP Employee/family member
Healthy volunteer children and adolescents:
* I.Q. \< 70
* Any serious medical condition or condition that interferes with fMRI scanning
* Pregnancy
* Past or current diagnosis of any anxiety disorder (panic disorder, GAD, Separation Anxiety Disorder, Social Phobia), mood disorder (manic or hypomanic episode, major depression), OCD, PTSD, Conduct Disorder, psychosis, current suicidal ideation, Tourette
* Disorder, Autism Spectrum Disorder or ADHD.
* Substance abuse within two months prior to study participation or present substance abuse
* History of sexual abuse.
* Parent or sibling with Bipolar Disorder, recurrent MDD, or any disorder with psychosis.
* NIMH IRP Employee family member
Parents of healthy volunteer children (Amish and Non-Amish) and Healthy Adults (not parents):
* IQ\< 70
* Any current psychiatric diagnosis
* NIMH IRP Employee/family member
Control subjects with ADHD but not BD:
* IQ\<70
* Pregnancy
* Ongoing medical illness or neurological disorder other than ADHD
* Any condition that would interfere with the participants ability to perform fMRI or other research tasks
* Current Major Depression
* Any past or present manic or hypomanic episode.
* NIMH IRP Employee family member
First- and Second-degree relatives of patients with BD:
* Active psychosis
* Dementia
* IQ \< 70
* Any clinical condition in need of immediate care
* Any chronic medical illness resulting in impaired CNS function
* Any condition that interferes with the participants ability to perform research tasks
* NIMH IRP Employee/family member
Amish Community children with BD:
* IQ\<70
* Active psychosis
* Any clinical condition in need of immediate care
* Any chronic medical illness resulting in impaired CNS function
* Any condition that would interfere with the participants ability to perform behavioral research tasks
* Limitations with English that would interfere with understanding consent/assent, interview, or task instructions.
* NIMH IRP Employee family member
Amish Community Adults with BD:
* Diagnosis of schizophrenia or other current psychosis.
* Any serious medical illness, such as heart, liver, or kidney disease.
* A history of drug or alcohol abuse in the past 90 days.
* Current or past seizure disorder
* Currently unstable hyperthyroidism or hypothyroidism
* Currently receiving medical treatment that would affect mood, such as steroids
* Active suicidal or homicidal thoughts or plans
* Limitations with English that would interfere with understanding consent/assent, interview, or task instructions.
* NIMH IRP Employee/family member
Amish Community at-risk subjects:
* IQ\<70
* Active psychosis
* Any clinical condition in need of immediate care
* Any chronic medical illness resulting in impaired CNS function
* Any condition that would interfere with the participants ability to perform behavioral research tasks
* Limitations with English that would interfere with understanding consent/assent, interview, or task instructions.
* NIMH IRP Employee family member
Amish Community healthy volunteer children \& adolescents:
* I.Q. \< 70
* Ongoing medical illness
* Neurological disorder (including seizures)
* Past or present substance abuse
* History of sexual abuse
* Limitations with English that would interfere with understanding consent/assent, interview or task instructions
* Past or present psychopathology in control subject or their first-degree relative
* NIMH IRP Employee family member
Amish Community adults who are parents of healthy volunteer children \& adolescents, healthy spouses of Amish adults with BD, or parents of adolescents with BD:
* I.Q. \< 70
* Ongoing medical illness
* Neurological disorder (including seizures)
* Past or present substance abuse
* History of sexual abuse
* Limitations with English that would interfere with understanding consent/assent, interview or task instructions
* NIMH IRP Employee/family member
* For Healthy volunteers: Past or present psychopathology in participant or their first-degree relative
* For Parents of healthy volunteer children: Past or present psychopathology as in (4) above.
In addition, children with BD (Section B.1.) who wish to receive treatment, including discontinuation of medication while inpatients on the pediatric behavioral health unit at NIH, may be eligible for treatment if they meet the following additional criteria:
Any contraindications for MRI scanning, plus claustrophobia or extreme separation anxiety
EXCLUSIONS for MRI Scanning:
* Pregnancy
* Substance abuse within two months of the initial evaluation, since alcohol and abused substances interfere with interpretation of fMRI and cognitive task data.
* Claustrophobia or anxiety that prevents participation in MRI
* Any serious medical condition or condition that interferes with fMRI scanning
* Metal in body which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if you were a welder or metal worker, since there may be
small metal fragments in the eye
\- Unable to lie comfortably on back for up to 90 minutes
* I.Q. \< 70
* Autistic disorder or more than mild autism spectrum disorder;
* Psychosis that interferes with the child s capacity to understand and comply with study procedures
* Unstable medical illness (e.g. severe asthma)
* Medical illness that could cause the symptoms of BSD (e.g. multiple sclerosis, thyroid disease)
* Pregnancy
* Substance abuse within two months of the initial evaluation, since alcohol and abused substances interfere with interpretation of fMRI and cognitive task data.
* NIMH IRP Employee family member
Adults with BD participating as individuals or as parents of at- risk children:
* Diagnosis of schizophrenia or other current psychosis.
* Claustrophobia or anxiety that prevents participation in MRI
* Any serious medical illness, such as heart, liver, or kidney disease.
* A history of drug or alcohol abuse in the past 90 days.
* Current or past seizure disorder
* Currently unstable hyperthyroidism or hypothyroidism
* Currently receiving medical treatment that would affect mood, such as steroids
* Pregnant or breast-feeding.
* Active suicidal or homicidal thoughts or plans
* NIMH IRP Employee/family member
Healthy volunteer children and adolescents:
* I.Q. \< 70
* Any serious medical condition or condition that interferes with fMRI scanning
* Pregnancy
* Past or current diagnosis of any anxiety disorder (panic disorder, GAD, Separation Anxiety Disorder, Social Phobia), mood disorder (manic or hypomanic episode, major depression), OCD, PTSD, Conduct Disorder, psychosis, current suicidal ideation, Tourette
* Disorder, Autism Spectrum Disorder or ADHD.
* Substance abuse within two months prior to study participation or present substance abuse
* History of sexual abuse.
* Parent or sibling with Bipolar Disorder, recurrent MDD, or any disorder with psychosis.
* NIMH IRP Employee family member
Parents of healthy volunteer children (Amish and Non-Amish) and Healthy Adults (not parents):
* IQ\< 70
* Any current psychiatric diagnosis
* NIMH IRP Employee/family member
Control subjects with ADHD but not BD:
* IQ\<70
* Pregnancy
* Ongoing medical illness or neurological disorder other than ADHD
* Any condition that would interfere with the participants ability to perform fMRI or other research tasks
* Current Major Depression
* Any past or present manic or hypomanic episode.
* NIMH IRP Employee family member
First- and Second-degree relatives of patients with BD:
* Active psychosis
* Dementia
* IQ \< 70
* Any clinical condition in need of immediate care
* Any chronic medical illness resulting in impaired CNS function
* Any condition that interferes with the participants ability to perform research tasks
* NIMH IRP Employee/family member
Amish Community children with BD:
* IQ\<70
* Active psychosis
* Any clinical condition in need of immediate care
* Any chronic medical illness resulting in impaired CNS function
* Any condition that would interfere with the participants ability to perform behavioral research tasks
* Limitations with English that would interfere with understanding consent/assent, interview, or task instructions.
* NIMH IRP Employee family member
Amish Community Adults with BD:
* Diagnosis of schizophrenia or other current psychosis.
* Any serious medical illness, such as heart, liver, or kidney disease.
* A history of drug or alcohol abuse in the past 90 days.
* Current or past seizure disorder
* Currently unstable hyperthyroidism or hypothyroidism
* Currently receiving medical treatment that would affect mood, such as steroids
* Active suicidal or homicidal thoughts or plans
* Limitations with English that would interfere with understanding consent/assent, interview, or task instructions.
* NIMH IRP Employee/family member
Amish Community at-risk subjects:
* IQ\<70
* Active psychosis
* Any clinical condition in need of immediate care
* Any chronic medical illness resulting in impaired CNS function
* Any condition that would interfere with the participants ability to perform behavioral research tasks
* Limitations with English that would interfere with understanding consent/assent, interview, or task instructions.
* NIMH IRP Employee family member
Amish Community healthy volunteer children \& adolescents:
* I.Q. \< 70
* Ongoing medical illness
* Neurological disorder (including seizures)
* Past or present substance abuse
* History of sexual abuse
* Limitations with English that would interfere with understanding consent/assent, interview or task instructions
* Past or present psychopathology in control subject or their first-degree relative
* NIMH IRP Employee family member
Amish Community adults who are parents of healthy volunteer children \& adolescents, healthy spouses of Amish adults with BD, or parents of adolescents with BD:
* I.Q. \< 70
* Ongoing medical illness
* Neurological disorder (including seizures)
* Past or present substance abuse
* History of sexual abuse
* Limitations with English that would interfere with understanding consent/assent, interview or task instructions
* NIMH IRP Employee/family member
* For Healthy volunteers: Past or present psychopathology in participant or their first-degree relative
* For Parents of healthy volunteer children: Past or present psychopathology as in (4) above.
In addition, children with BD (Section B.1.) who wish to receive treatment, including discontinuation of medication while inpatients on the pediatric behavioral health unit at NIH, may be eligible for treatment if they meet the following additional criteria:
Any contraindications for MRI scanning, plus claustrophobia or extreme separation anxiety
EXCLUSIONS for MRI Scanning:
* Pregnancy
* Substance abuse within two months of the initial evaluation, since alcohol and abused substances interfere with interpretation of fMRI and cognitive task data.
* Claustrophobia or anxiety that prevents participation in MRI
* Any serious medical condition or condition that interferes with fMRI scanning
* Metal in body which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if you were a welder or metal worker, since there may be
small metal fragments in the eye
\- Unable to lie comfortably on back for up to 90 minutes
Minimum Eligible Age
3 Years
Maximum Eligible Age
58 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ellen Leibenluft, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Mental Health (NIMH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Geller B, Sun K, Zimerman B, Luby J, Frazier J, Williams M. Complex and rapid-cycling in bipolar children and adolescents: a preliminary study. J Affect Disord. 1995 Aug 18;34(4):259-68. doi: 10.1016/0165-0327(95)00023-g.
Reference Type
BACKGROUND
Wozniak J, Biederman J, Kiely K, Ablon JS, Faraone SV, Mundy E, Mennin D. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):867-76. doi: 10.1097/00004583-199507000-00010.
Reference Type
BACKGROUND
Faedda GL, Baldessarini RJ, Suppes T, Tondo L, Becker I, Lipschitz DS. Pediatric-onset bipolar disorder: a neglected clinical and public health problem. Harv Rev Psychiatry. 1995 Nov-Dec;3(4):171-95. doi: 10.3109/10673229509017185.
Reference Type
BACKGROUND
Chen G, Taylor PA, Reynolds RC, Leibenluft E, Pine DS, Brotman MA, Pagliaccio D, Haller SP. BOLD Response is more than just magnitude: Improving detection sensitivity through capturing hemodynamic profiles. Neuroimage. 2023 Aug 15;277:120224. doi: 10.1016/j.neuroimage.2023.120224. Epub 2023 Jun 15.
Reference Type
DERIVED
Haller SP, Archer C, Jeong A, Jaffe A, Jones EL, Harrewijn A, Naim R, Linke JO, Stoddard J, Brotman MA. Changes in Internalizing Symptoms During the COVID-19 Pandemic in a Transdiagnostic Sample of Youth: Exploring Mediators and Predictors. Child Psychiatry Hum Dev. 2024 Feb;55(1):206-218. doi: 10.1007/s10578-022-01382-z. Epub 2022 Jul 6.
Reference Type
DERIVED
Zik J, Deveney CM, Ellingson JM, Haller SP, Kircanski K, Cardinale EM, Brotman MA, Stoddard J. Understanding Irritability in Relation to Anger, Aggression, and Informant in a Pediatric Clinical Population. J Am Acad Child Adolesc Psychiatry. 2022 May;61(5):711-720. doi: 10.1016/j.jaac.2021.08.012. Epub 2021 Aug 23.
Reference Type
DERIVED
Scheinost D, Dadashkarimi J, Finn ES, Wambach CG, MacGillivray C, Roule AL, Niendam TA, Pine DS, Brotman MA, Leibenluft E, Tseng WL. Functional connectivity during frustration: a preliminary study of predictive modeling of irritability in youth. Neuropsychopharmacology. 2021 Jun;46(7):1300-1306. doi: 10.1038/s41386-020-00954-8. Epub 2021 Jan 21.
Reference Type
DERIVED
Haller SP, Stoddard J, Pagliaccio D, Bui H, MacGillivray C, Jones M, Brotman MA. Computational Modeling of Attentional Impairments in Disruptive Mood Dysregulation and Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2021 May;60(5):637-645. doi: 10.1016/j.jaac.2020.08.468. Epub 2020 Nov 24.
Reference Type
DERIVED
Haller SP, Kircanski K, Stringaris A, Clayton M, Bui H, Agorsor C, Cardenas SI, Towbin KE, Pine DS, Leibenluft E, Brotman MA. The Clinician Affective Reactivity Index: Validity and Reliability of a Clinician-Rated Assessment of Irritability. Behav Ther. 2020 Mar;51(2):283-293. doi: 10.1016/j.beth.2019.10.005. Epub 2019 Nov 27.
Reference Type
DERIVED
Leibenluft E. Chronic irritability in children is not pediatric bipolar disorder: Implications for treatment. Bipolar Disord. 2020 Mar;22(2):195-196. doi: 10.1111/bdi.12881. Epub 2019 Dec 19. No abstract available.
Reference Type
DERIVED
Linke JO, Adleman NE, Sarlls J, Ross A, Perlstein S, Frank HR, Towbin KE, Pine DS, Leibenluft E, Brotman MA. White Matter Microstructure in Pediatric Bipolar Disorder and Disruptive Mood Dysregulation Disorder. J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1135-1145. doi: 10.1016/j.jaac.2019.05.035. Epub 2019 Jul 19.
Reference Type
DERIVED
Cardinale EM, Kircanski K, Brooks J, Gold AL, Towbin KE, Pine DS, Leibenluft E, Brotman MA. Parsing neurodevelopmental features of irritability and anxiety: Replication and validation of a latent variable approach. Dev Psychopathol. 2019 Aug;31(3):917-929. doi: 10.1017/S095457941900035X. Epub 2019 May 8.
Reference Type
DERIVED
Kryza-Lacombe M, Brotman MA, Reynolds RC, Towbin K, Pine DS, Leibenluft E, Wiggins JL. Neural mechanisms of face emotion processing in youths and adults with bipolar disorder. Bipolar Disord. 2019 Jun;21(4):309-320. doi: 10.1111/bdi.12768. Epub 2019 Apr 1.
Reference Type
DERIVED
Tseng WL, Deveney CM, Stoddard J, Kircanski K, Frackman AE, Yi JY, Hsu D, Moroney E, Machlin L, Donahue L, Roule A, Perhamus G, Reynolds RC, Roberson-Nay R, Hettema JM, Towbin KE, Stringaris A, Pine DS, Brotman MA, Leibenluft E. Brain Mechanisms of Attention Orienting Following Frustration: Associations With Irritability and Age in Youths. Am J Psychiatry. 2019 Jan 1;176(1):67-76. doi: 10.1176/appi.ajp.2018.18040491. Epub 2018 Oct 19.
Reference Type
DERIVED
Stringaris A, Vidal-Ribas P, Brotman MA, Leibenluft E. Practitioner Review: Definition, recognition, and treatment challenges of irritability in young people. J Child Psychol Psychiatry. 2018 Jul;59(7):721-739. doi: 10.1111/jcpp.12823. Epub 2017 Oct 30.
Reference Type
DERIVED
Brotman MA, Kircanski K, Leibenluft E. Irritability in Children and Adolescents. Annu Rev Clin Psychol. 2017 May 8;13:317-341. doi: 10.1146/annurev-clinpsy-032816-044941.
Reference Type
DERIVED
Brotman MA, Kircanski K, Stringaris A, Pine DS, Leibenluft E. Irritability in Youths: A Translational Model. Am J Psychiatry. 2017 Jun 1;174(6):520-532. doi: 10.1176/appi.ajp.2016.16070839. Epub 2017 Jan 20.
Reference Type
DERIVED
Wiggins JL, Brotman MA, Adleman NE, Kim P, Wambach CG, Reynolds RC, Chen G, Towbin K, Pine DS, Leibenluft E. Neural Markers in Pediatric Bipolar Disorder and Familial Risk for Bipolar Disorder. J Am Acad Child Adolesc Psychiatry. 2017 Jan;56(1):67-78. doi: 10.1016/j.jaac.2016.10.009. Epub 2016 Nov 2.
Reference Type
DERIVED
Tseng WL, Thomas LA, Harkins E, Stoddard J, Zarate CA Jr, Pine DS, Leibenluft E, Brotman MA. Functional connectivity during masked and unmasked face emotion processing in bipolar disorder. Psychiatry Res Neuroimaging. 2016 Dec 30;258:1-9. doi: 10.1016/j.pscychresns.2016.10.006. Epub 2016 Oct 24.
Reference Type
DERIVED
Stoddard J, Gotts SJ, Brotman MA, Lever S, Hsu D, Zarate C, Ernst M, Pine DS, Leibenluft E. Aberrant intrinsic functional connectivity within and between corticostriatal and temporal-parietal networks in adults and youth with bipolar disorder. Psychol Med. 2016 May;46(7):1509-22. doi: 10.1017/S0033291716000143. Epub 2016 Feb 29.
Reference Type
DERIVED
Wiggins JL, Brotman MA, Adleman NE, Kim P, Oakes AH, Reynolds RC, Chen G, Pine DS, Leibenluft E. Neural Correlates of Irritability in Disruptive Mood Dysregulation and Bipolar Disorders. Am J Psychiatry. 2016 Jul 1;173(7):722-30. doi: 10.1176/appi.ajp.2015.15060833. Epub 2016 Feb 19.
Reference Type
DERIVED
Stoddard J, Sharif-Askary B, Harkins EA, Frank HR, Brotman MA, Penton-Voak IS, Maoz K, Bar-Haim Y, Munafo M, Pine DS, Leibenluft E. An Open Pilot Study of Training Hostile Interpretation Bias to Treat Disruptive Mood Dysregulation Disorder. J Child Adolesc Psychopharmacol. 2016 Feb;26(1):49-57. doi: 10.1089/cap.2015.0100. Epub 2016 Jan 8.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2000-M-0198.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00-M-0198
Identifier Type: -
Identifier Source: secondary_id
000198
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
PET and MRI Brain Imaging of Bipolar Disorder
NCT01880957
COMPLETED
NA
White Matter in Pediatric Bipolar Disorder: A DTI Study
NCT00391235
COMPLETED
Neurofeedback for Bipolar Disorder
NCT05802446
RECRUITING
NA
Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents
NCT00332098
COMPLETED
PHASE3
Early Family-Focused Treatment for Youth at Risk for Bipolar Disorder
NCT00943085
COMPLETED
NA
Children's Bipolar Network Treatment Trial I
NCT05427123
RECRUITING
Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder
NCT00592267
UNKNOWN
Evaluation of Brain MRI and Clinical Characteristics of Adolescents With Bipolar Disorder and Children of Parents With Bipolar Disorder
NCT01678989
UNKNOWN
Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents
NCT00036582
COMPLETED
PHASE3
A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder
NCT03017781
COMPLETED
The Evaluation and Follow-up of Patients With Bipolar Disorder
NCT00001652
COMPLETED
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
NCT00596622
COMPLETED
PHASE4
Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania
NCT00457054
COMPLETED
PHASE4
Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation
NCT00801567
WITHDRAWN
NA
Spectroscopy in Children and Adolescents With Bipolar Disorder
NCT00181831
COMPLETED
Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
NCT01811147
COMPLETED
PHASE4
Juvenile Bipolar Disorder Outpatient Program
NCT01000402
UNKNOWN
PHASE4
Functional and Neurochemical Brain Changes in First-episode Bipolar Mania
NCT00609193
COMPLETED
Functional Remediation for Bipolar Disorder
NCT03403179
COMPLETED
NA
Early Intervention for Youth at Risk for Bipolar Disorder
NCT01483391
COMPLETED
NA
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
NCT00194077
COMPLETED
PHASE3
Treatment of Depression in Youth With Bipolar Disorders
NCT00005015
TERMINATED
PHASE3
Reproductive Function and Mood in Women With Bipolar Disorder
NCT00183352
COMPLETED
MAPP: Imagery-focused Therapy for Bipolar Disorder
NCT01981018
COMPLETED
NA
Evaluation of Patients With Rapid Cycling Bipolar Disorder (RCBD)
NCT00001772
COMPLETED